This randomized controlled trial compares two common medications, labetalol and extended-release nifedipine, to determine which is more effective at managing postpartum high blood pressure. We hypothesize that extended-release nifedipine will better control blood pressure and reduce the need for continued medication beyond six weeks postpartum. The study will enroll 110 postpartum participants, randomly assigning them to one of the two medications, with remote blood pressure monitoring to evaluate treatment effectiveness and inform postpartum hypertension management.
None
None
Parallel
Labetalol
DrugLabetalol is a beta-blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral labetalol will be initiated at 200mg twice or three times daily and adjusted up to 2400 mg/day as needed for blood pressure control.
Nifedipine
DrugNifedipine is a calcium channel blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral extended-release nifedipine will be initiated at 30mg once daily and adjusted up to 120mg/day as needed for blood pressure control.
Continuation of antihypertensive medication
The proportion of participants who continue to require antihypertensive medication beyond 6 weeks postpartum
Postpartum hospital readmission
The number of participants requiring hospital readmission for hypertension-related complications.
Treatment failure
The proportion of participants requiring a medication switch or the addition of a second antihypertensive agent to achieve blood pressure control.
Patient-reported medication side effects
The frequency and type of medication-related side effects reported by participants.
Click on the lead sponsor to view all of their trials.
